Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Lung Diseases 1Liposarcoma 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma 1Advanced or Metastatic Solid Malignancies 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Melanoma × sitravatinib × Clear all
NCT05542342 2026-06-01

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed
16 enrolled 14 charts
Dermatologic

Melanoma

NCT05104801 2021-11-04

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
37 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡